Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

* Age \>18 years - Clinical diagnosis of SCD (HbSS, HbSC, HbSβ+; Thal, HbSβ0Thal, HbS variants) - Baseline score of 60 or lower on the ASCQ-Me 7-day pain interference domain - If on a SCD modifying therapy (hydroxyurea, regular blood transfusions, L-glutamine, voxelotor, crizanlizumab), on stable dose for at least 3 months - If using opioids for pain at home, on stable dose for at least 3 months - One urine toxicology negative for cannabinoids within 30 days of randomization - No known intolerance to dronabinol, or marijuana - No history of psychotic episode, psychosis, or active suicidality - No contraindication to dronabinol with attention to potential side effects, concurrent medications/substances, and concurrent medical problems, as evaluated by a physician - Willing to abstain from cannabis, medical and illicit, during study weeks 1 through 8 - Not pregnant or nursing - If a woman capable of becoming pregnant, willing to use a medically accepted form of birth control for the duration of study participation. Accepted forms include oral contraception, medroxyprogesterone, contraceptive implants or patch, surgical sterilization, total abstinence. - Able to consent for research - No daily cannabis use - No diagnosis of active substance use disorder Always talk to your doctor about whether this trial is right for you.